Sort   by:  
 Page size 
GenomicsIdasanutlin differential expression in MOLM13 and OCIAML3
Idasanutlin differential expression in MOLM13 and OCIAML3
PRJNA1005281 | ENA
GenomicsLong term and short term Idasanutlin treatments in SCCOHT cell lines
Long term and short term Idasanutlin treatments in SCCOHT cell lines
PRJEB111900 | ENA
GenomicsGenome-wide CRISPR screen of MOLM13 cells after Idasanutlin treatment
Genome-wide CRISPR screen of MOLM13 cells after Idasanutlin treatment
PRJNA1005974 | ENA
TranscriptomicsLong term and short term Idasanutlin treatments in SCCOHT cell lines
RNA-seq samples in SCCOHT-1 and COV434 for idasanutlin treatment (0.5μM, 24h), and RNA-seq samples in BIN-67 and COV434 for short-term idasanutlin treatment (0.5μM, 3h). The goal of the experiment is to assess the genes that are regulated by p53 stabilization in the long term or short term using ida...
ORGANISM(S): Homo sapiens 
2026-05-05 | E-MTAB-16956 | biostudies-arrayexpress
TranscriptomicsIdasanutlin differential expression in MOLM13 and OCIAML3
Targeting MDM2 is an attractive therapeutic approach for TP53 wild-type (WT) tumors, including the majority of de novo acute myeloid leukemia (AML) cases. However, patients with WT TP53 have shown variable responses to MDM2 inhibitors in clinical trials, highlighting the need to identify additional ...
ORGANISM(S): Homo sapiens 
2024-08-15 | GSE240805 | GEO
UnknownOral idasanutlin in patients with polycythemia vera.
Not available
S-EPMC6688433 | biostudies-literature
OtherGenome-wide CRISPR screen of MOLM13 cells after Idasanutlin treatment
Targeting MDM2 is an attractive therapeutic approach for TP53 wild-type (WT) tumors, including the majority of de novo acute myeloid leukemia (AML) cases. However, patients with WT TP53 have shown variable responses to MDM2 inhibitors in clinical trials, highlighting the need to identify additional ...
ORGANISM(S): Homo sapiens synthetic construct 
2024-08-15 | GSE240977 | GEO
UnknownLack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
Not available
S-EPMC6373577 | biostudies-literature
UnknownTransient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.
Not available
S-EPMC7686898 | biostudies-literature
UnknownProlonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells.
Not available
S-EPMC6266412 | biostudies-literature
Sort   by:  
 Page size